The Life Sciences team advised Intellia Therapeutics, Inc. (“Intellia”) on the pricing of an underwritten public offering of 19,255,815 shares of its common stock. The shares of common stock sold included 2,511,628 shares pursuant to an option granted by Intellia to the underwriters, which option was exercised in full. The shares of common stock were sold at a public offering price of $10.75 per share. The aggregate net proceeds to Intellia from this offering were $194.6 million before deducting underwriting discounts and commissions and other estimated offering expenses.
Intellia is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine by leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical, and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease.
The Goodwin team was led by Gaby Morales-Rivera, Michael Bison, Gaby Boria, Julia Novick, Hugh Rennie, Susan Lee, Krupa Zachariah, Maggie Wong, Gozde Guckaya, with invaluable assistance from Krisn Modi and Ysabelle Regis.
For more information on the deal, please read the press release.